natgillin/translations-raw huggingface dataset:
Across all these themes, support for trans-national cooperation will be implemented through:
V okviru vseh teh tém se bo podpora nadnacionalnemu sodelovanju izvajala s pomočjo:
Collaborative research,
skupnega raziskovanja,
Joint Technology Initiatives,
skupnih tehnoloških pobud,
Coordination of non-Community research programmes,
usklajevanja neskupnostnih raziskovalnih programov,
International cooperation.
mednarodnega sodelovanja.
Collaborative Research
Skupno raziskovanje
Collaborative research will constitute the bulk and the core of Community research funding.
Skupnemu raziskovanju bo namenjen večji in osrednji del sredstev Skupnosti za raziskovanje.
The objective is to establish, in the major fields of advancement of knowledge, excellent research projects and networks able to attract researchers and investments from Europe and the entire world.
Cilj je na glavnih področjih razvijanja znanja vzpostaviti odlične raziskovalne projekte in omrežja, ki lahko privabijo raziskovalce in naložbe iz Evrope in celega sveta.
This will be achieved by supporting collaborative research through a range of funding schemes: collaborative projects, networks of excellence, coordination/support actions (see Annex III).
To bo doseženo s pomočjo podpore skupnemu raziskovanju preko vrste shem financiranja: skupnih projektov, mrež odličnosti, usklajevalnih/podpornih dejavnosti (glej Prilogo III).
Joint Technology Initiatives
Skupne tehnološke pobude
In a very limited number of cases, the scope of an RTD objective and the scale of the resources involved could justify setting up long term public private partnerships in the form of Joint Technology Initiatives.
V zelo omejenem številu primerov bi obseg cilja RTR in razpon vključenih virov lahko upravičila vzpostavitev dolgoročnih partnerstev javnega in zasebnega sektorja v obliki skupnih tehnoloških pobud.
These initiatives, mainly resulting from the work of European Technology Platforms and covering one or a small number of selected aspects of research in their field, will combine private sector investment and national and European public funding, including grant funding from the Seventh Framework Programme and loan and guarantee finance from the European Investment Bank.
Te pobude, ki večinoma izhajajo iz delovanja evropskih tehnoloških platform in zajemajo en vidik ali majhno število izbranih vidikov raziskav na njihovem področju, bodo združevale naložbe zasebnega sektorja in javno financiranje na nacionalni in evropski ravni, vključno s financiranjem z nepovratnimi sredstvi iz okvirnega raziskovalnega programa in financiranjem posojil in jamstev s strani Evropske investicijske banke.
Each Joint Technology Initiative will be decided upon individually, either on the basis of Article 171 of the Treaty (this may include the creation of a joint undertaking) or on the basis of Specific Programme Decisions in accordance with Article 166(3) of the Treaty.
Odločitve glede posameznih skupnih tehnoloških pobud bodo sprejete za vsak primer posebej, bodisi na podlagi člena 171 Pogodbe (to lahko vključuje ustanovitev skupnega podjetja) bodisi na podlagi odločb v zvezi s posebnimi programi v skladu s členom 166(3) Pogodbe.
Potential Joint Technology Initiatives will be identified in an open and transparent way on the basis of an evaluation using a series of criteria:
Morebitne skupne tehnološke pobude bodo določene na odprt in pregleden način na podlagi ocenjevanja, pri katerem se bo upoštevala vrsta meril:
added value of European-level intervention,
dodana vrednost delovanja na evropski ravni,
the degree and clarity of definition of the objective and deliverables to be pursued,
stopnja in jasnost opredelitve cilja in končnih rezultatov, za katere si je treba prizadevati,
strength of the financial and resource commitment from industry,
trdnost zavezanosti industrije glede finančnih sredstev in virov,
capacity to attract additional national support and leverage current and future industry funding.
zmožnost privabljanja dodatne nacionalne podpore ter povečanja sedanjega in prihodnjega financiranja s strani industrije.
The nature of the Joint Technology Initiatives must be clearly defined, in particular with regard to matters concerning:
Naravo skupnih tehnoloških pobud je treba jasno opredeliti, zlasti v zvezi s:
financial commitments,
finančnimi obveznostmi,
duration of the commitment of the participants,
trajanjem obveznosti udeležencev,
rules for entering and exiting the contract,
pravili za sklenitev in prekinitev pogodbe,
Considering the particular scope and complexity of the Joint Technology Initiatives, strong efforts will be made to ensure their transparent operation and to ensure that any allocation of Community funding by the Joint Technology Initiatives takes place on the basis of the Framework Programme principles of excellence and competition.
Ob upoštevanju posebnega področja uporabe in zahtevnosti skupnih tehnoloških pobud si bo treba močno prizadevati za zagotovitev preglednosti njihovega delovanja in za dodelitev finančnih sredstev Skupnosti v okviru skupnih tehnoloških pobud v skladu z načeli odličnosti in konkurence iz okvirnega programa.
Particular attention will be paid to the overall coherence and coordination between Joint Technology Initiatives and programmes and projects in the same fields [2], while respecting their existing implementation procedures, as well as to ensuring that participation in their projects is open to a wide range of participants throughout Europe, in particular SMEs.
Posebna pozornost bo namenjena splošni medsebojni povezanosti in uskladitvi med skupnimi tehnološkimi pobudami ter programi in projekti na istih področjih [2], pri čemer je treba upoštevati obstoječe postopke izvajanja; hkrati pa tudi zagotoviti, da bodo v njihovih projektih lahko sodeloval širok krog udeležencev iz vse Evrope, zlasti MSP.
Coordination of Non-Community Research Programmes
Usklajevanje raziskovalnih programov izven okvira Skupnosti
The action undertaken in this field will make use of two main tools: the ERA-NET scheme and the participation of the Community in jointly implemented national research programmes (under Article 169 of the Treaty).
V okviru ukrepov na tem področju, se bosta uporabljali dve glavni orodji: shema ERA-NET in sodelovanje Skupnosti pri nacionalnih raziskovalnih programih, ki se izvajajo skupno (po členu 169 Pogodbe).
The action may cover subjects not directly linked to the ten themes in so far as they have sufficient European added value.
Ukrep lahko zajema področja, ki niso neposredno povezana z desetimi temami, v kolikor imajo ta zadostno evropsko dodano vrednost.
The action will also be used to enhance the complementarity and synergy between the Seventh Framework Programme and activities carried out in the framework of intergovernmental structures such as EUREKA and COST [3].
Poleg tega se bosta z ukrepom krepila dopolnjevanje in sinergija med okvirnim programom in dejavnostmi, ki se izvajajo v okviru medvladnih struktur, kot sta EUREKA in COST [3].
providing a framework for actors implementing public research programmes to step up the coordination of their activities.
z zagotavljanjem okvira za akterje, ki izvajajo javne raziskovalne programe, da bi pospešili usklajevanje njihovih dejavnosti.
in a limited number of cases, providing additional Community financial support to those participants that pool resources for the purpose of joint calls for proposals between their respective national and regional programmes (‘ERA-NET PLUS’).
v omejenem številu primerov z zagotavljanjem dodatne finančne podpore Skupnosti tistim udeležencem, ki združujejo sredstva za namen skupnih razpisov v okviru njihovih nacionalnih in regionalnih programov („ERA-NET PLUS“).
The participation of the Community in research programmes jointly implemented on the basis of Article 169 of the Treaty is especially relevant to European cooperation on a large scale in ‘variable geometry’ between Member States sharing common needs and/or interests.
Sodelovanje Skupnosti v raziskovalnih programih, ki se izvajajo skupno na podlagi člena 169 Pogodbe, je posebej pomembno za obsežnejše evropsko sodelovanje v „spremenljivi geometriji“ med državami članicami, ki imajo enake potrebe in/ali interese.
In well-identified cases such Article 169 initiatives could be launched in areas to be identified in close association with the Member States, including the possible cooperation with intergovernmental programmes, on the basis of a series of criteria:
V natančno opredeljenih primerih bi lahko take pobude v skladu s členom 169 sprožili na področjih, ki jih je treba opredeliti v tesni povezavi z državami članicami, vključno z možnim sodelovanjem z medvladnimi programi, na podlagi vrste meril:
relevance to Community objectives,
pomembnost za cilje Skupnosti,
the clear definition of the objective to be pursued and its relevance to the objectives of this Framework Programme,
jasna opredelitev cilja, ki mu je treba slediti, in njegova pomembnost za cilje tega okvirnega programa,
presence of a pre-existing basis (existing or envisaged research programmes),
prisotnost že obstoječe osnove (obstoječi ali predvideni raziskovalni programi),
European added value,
evropska dodana vrednost,
critical mass, with regard to the size and the number of programmes involved and the similarity of activities they cover,
kritična masa ob upoštevanju obsega in števila vključenih programov, in podobnost dejavnosti, ki jih zajemajo,
efficiency of Article 169 as the most appropriate means for achieving the objectives.
učinkovitost člena 169 kot najprimernejšega sredstva za doseganje ciljev.
International Cooperation
Mednarodno sodelovanje
International cooperation actions, showing European added value and being of mutual interest, under this part of the Seventh Framework Programme will be:
V tem delu Okvirnega programa bodo ukrepi za mednarodno sodelovanje, ki morajo izkazovati evropsko dodano vrednost in biti v skupnem interesu, naslednji:
actions designed to enhance participation of researchers and research institutions from third countries in the thematic areas, with appropriate restrictions for the security theme due to the confidentiality aspects, accompanied by strong efforts to encourage them to seize this opportunity.
Ukrepi namenjeni okrepitvi sodelovanja raziskovalcev in raziskovalnih institucij iz tretjih držav na tematskih področjih — pri tem bodo za temo „Varnost“ veljale ustrezne omejitve zaradi zaupne narave dejavnosti — pri čemer jih je treba še posebej spodbujati, naj izkoristijo to priložnost.
Specific cooperation actions in each thematic area dedicated to third countries where there is mutual interest in co-operating on particular topics selected on the basis of the scientific and technological level and needs of the countries concerned.
Posebni ukrepi sodelovanja na vsakem tematskem področju, namenjenemu tretjim državam, kjer je skupni interes za sodelovanje pri posebnih temah, izbranih na podlagi znanstvenih in tehnoloških ravni in potreb zadevnih držav.
Closely associated with the bilateral cooperation agreements or multilateral dialogues between the EU and these countries or groups of countries, these actions will serve as privileged tools for implementing the cooperation between the EU and these countries.
Ti ukrepi bodo v tesni povezavi z dvostranskimi sporazumi o sodelovanju ali večstranskimi dialogi med EU in temi državami ali skupinami držav služili kot prednostna orodja za izvajanje sodelovanja med EU in temi državami.
Such actions are, in particular, actions aiming at reinforcing the research capacities of candidate countries as well as neighbourhood countries and cooperative activities targeted at developing and emerging countries, focusing on their particular needs in fields such as health, including research into neglected diseases, agriculture, fisheries and environment, and implemented in financial conditions adapted to their capacities.
Med te ukrepe spadajo zlasti: ukrepi, namenjeni krepitvi raziskovalnih zmogljivosti držav kandidatk ter tudi sosednjih držav in dejavnosti sodelovanja, namenjene državam v razvoju in razvijajočim se državam, s poudarkom na njihovih posebnih potrebah na področjih, kot so zdravje, vključno z raziskavami zapostavljenih bolezni, kmetijstvo, ribištvo in okolje, ter izvedene v finančnih pogojih, prilagojenih njihovim zmogljivostim.
This part of the Framework Programme covers the international cooperation actions in each thematic area and across themes.
Ta del Okvirnega programa vključuje dejavnosti mednarodnega sodelovanja na vsakem tematskem področju in na področjih, ki zadevajo več tem.
Such actions will be implemented in coordination with those under the ‘People’ and the ‘Capacities’ programmes.
Te dejavnosti se bodo izvajale v povezavi z dejavnostmi iz programov „Ljudje“ in „Zmogljivosti“.
An overall strategy for international cooperation within the Seventh Framework Programme will underpin this activity.
To delovanje bo podprto s celovito strategijo mednarodnega sodelovanja v okviru Sedmega okvirnega programa.
Improving the health of European citizens and increasing the competitiveness and boosting the innovative capacity of European health-related industries and businesses, while addressing global health issues including emerging epidemics.
Izboljšanje zdravja evropskih državljanov ter povečanje konkurenčnosti in inovativne zmogljivosti evropskih industrijskih sektorjev in podjetij, povezanih z zdravjem, ob obravnavi svetovnih zdravstvenih problemov, vključno s pojavljajočimi se epidemijami.
Emphasis will be put on translational research (translation of basic discoveries into clinical applications including scientific validation of experimental results), the development and validation of new therapies, methods for health promotion and prevention, including promotion of child health, healthy ageing, diagnostic tools and medical technologies, as well as sustainable and efficient healthcare systems.
Poudarek bo na translacijskih raziskavah (prenos temeljnih odkritij v klinično prakso, vključno z znanstvenim potrjevanjem rezultatov poskusov), na razvijanju in potrjevanju novih terapij, metod za spodbujanje zdravja in preventivo, tudi za spodbujanje zdravja otrok, zdravega staranja, diagnostičnega orodja in medicinskih tehnologij ter tudi na trajnostnih in učinkovitih sistemih zdravstvenega varstva.
The sequencing of the human genome and the recent advances in post-genomics have revolutionised research into human health and diseases.
Zaporedje človeškega genoma in nedavni napredek v postgenomiki sta revolucionirala raziskave na področju človekovega zdravja in bolezni.
Integrating the vast amounts of data, understanding underlying biological processes and developing key technologies for health-related bio-industries requires the bringing together of critical masses of various expertise and resources that are not available at a national level, with a view to developing knowledge and capacity for intervention.
Vključevanje obsežne količine podatkov, razumevanja osnovnih bioloških procesov in razvoj ključnih tehnologij za bioindustrijske sektorje, ki so povezani z zdravjem, zahtevata povezovanje kritične mase različnih strokovnih znanj in izkušenj ter virov, ki niso na voljo na nacionalni ravni, z namenom razvijanja znanja in zmogljivosti za posredovanje.
Significant advances in translational health research, which is essential to ensure that biomedical research provides practical benefits and improves life quality, also require multidisciplinary and pan-European approaches involving different stakeholders.
Pomemben napredek na področju translacijskih zdravstvenih raziskav je bistven za zagotovitev praktičnih koristi biomedicinskih raziskav in omogoča izboljšanje kakovosti življenja, zahteva pa tudi multidisciplinarne in vseevropske pristope, ki vključujejo različne zainteresirane strani.
Such approaches allow Europe to contribute more effectively to international efforts to combat diseases of global importance.
Takšni pristopi omogočajo Evropi, da bolj učinkovito prispeva k mednarodnim prizadevanjem za boj proti boleznim svetovnega pomena.
Clinical research on many diseases (e.g. cancer, cardiovascular and infectious diseases, mental and neurological diseases, in particular those linked with ageing, such as Alzheimer and Parkinson diseases) relies on international multi-centre trials to achieve the required number of patients in a short time-frame.
Klinične raziskave številnih bolezni (npr. rak, bolezni srca in ožilja ter nalezljive bolezni, duševne in nevrološke bolezni, zlasti tiste, povezane s staranjem, kot sta Alzheimerjeva in Parkinsonova bolezen) temeljijo na mednarodnih poskusih v več središčih, da bi v kratkem časovnem okviru dobili zahtevano število pacientov.
Epidemiological research requires a large diversity of populations and international networks to reach significant conclusions.
Epidemiološke raziskave zahtevajo veliko raznovrstnost populacij in mednarodnih omrežij, da bi prišli do pomembnih ugotovitev.
Developing new diagnostics and treatments for rare disorders, as well as performing epidemiological research on those disorders, also requires multi-country approaches to increase the number of patients for each study.
Razvijanje novih možnosti za diagnosticiranje in zdravljenje redkih zdravstvenih motenj, kakor tudi izvajanje epidemioloških raziskav teh zdravstvenih motenj, prav tako zahtevata večdržavne pristope, da bi povečali število pacientov za vsako študijo.
In addition, performing health policy-driven research at the European level enables comparisons to be made of the models, systems, data, and patient material held in national databases and biobanks.
Poleg tega izvajanje raziskav, ki jih usmerja zdravstvena politika, na evropski ravni omogoča primerjave modelov, sistemov, podatkov in vzorcev pacientov, shranjenih v nacionalnih podatkovnih zbirkah in biobankah.
Strong EU-based biomedical research will help strengthen the competitiveness of the European healthcare biotechnology, medical technology and pharmaceutical industries.
Obsežne biomedicinske raziskave na ravni EU bodo pomagale okrepiti konkurenčnost evropske biotehnologije na področju zdravstvenega varstva, medicinske tehnologije in farmacevtske industrije.
EU collaboration with developing countries will allow those countries to develop research capacities.
Sodelovanje EU z državami v razvoju bo tem državam omogočilo razvoj raziskovalnih zmogljivosti.
The EU must also play an active role in creating an environment conducive to innovation in public and pharmaceutical sectors which address public health needs, in particular to maximise the success of clinical research.
EU mora igrati dejavno vlogo tudi pri ustvarjanju okolja, ki spodbuja inovativnost v javnem in farmacevtskem sektorju, ki obravnavata potrebe javnega zdravja, zlasti pri doseganju čim večjega uspeha kliničnih raziskav.
Research-based SMEs are the main economic drivers of the healthcare biotechnology and medical technology industries.
MSP, dejavna na področju raziskav, predstavljajo glavno gospodarsko gonilno silo za industrijo biotehnologije in medicinske tehnologije na področju zdravstvenega varstva.
Although Europe now has more biotechnology companies than the US, most of them are small and less mature than their competitors.
Čeprav ima Evropa trenutno več družb na področju biotehnologije kot ZDA, so te večinoma majhne in manj razvite od njihovih konkurentov.
Public-private research efforts at the EU level will facilitate their development.
Javno-zasebna raziskovalna prizadevanja na ravni EU bodo olajšala njihov razvoj.
EU research will also contribute to the development of new norms and standards to set up an appropriate legislative framework for new medical technologies (e.g. regenerative medicine).
Raziskave EU bodo prispevale tudi k razvoju novih normativov in standardov za vzpostavitev ustreznega pravnega okvira za nove medicinske tehnologije (npr. regenerativna medicina).
The global leadership of European research and innovation in the field of alternative testing strategies, in particular non-animal methods, should be ensured.
Zagotoviti bi bilo treba vodilni položaj na svetovni ravni evropskega raziskovanja in inovacij na področju alternativnih strategij testiranja, predvsem z metodami, ki ne vključujejo živali.
The activities that will be addressed, which include research essential to policy requirements, are set out below.
V nadaljevanju so navedene dejavnosti, ki bodo obravnavane in vključujejo raziskave, bistvene z vidika zahtev politike.
Long-term research agendas such as those established by European Technology Platforms, such as the one on innovative medicines, will be supported where relevant.
Po potrebi bo podpora namenjena tudi dolgoročnim programom raziskav, kot so tisti, ki so jih določile evropske tehnološke platforme, na primer raziskavam v zvezi z inovativnimi zdravili.
To respond to new policy needs, additional actions may be supported in, for example, the areas of health policy issues and occupational health and safety.
Kot odgovor na nove potrebe politike se bo lahko podprlo dodatne ukrepe, na primer na področju vprašanj zdravstvene politike ter varnosti in zdravja pri delu.
The strategic issues of child health and paediatric diseases as well as of the health of the ageing population will receive specific attention and will have to be taken into account whenever appropriate across all activities in this theme.
Posebne pozornosti bodo deležna strateška vprašanja zdravja otrok in otroških boleznih ter zdravja starajočega se prebivalstva; ta strateška vprašanja bodo po potrebi upoštevana v vseh dejavnostih, ki jih zajema ta tema.
Ethical, legal and socio-economic issues will be taken into account within each of the following activities.
Pri vseh dejavnostih se bodo upoštevala etična, pravna in družbeno-ekonomska vprašanja.
Biotechnology, generic tools and medical technologies for human health
Biotehnologija, generična orodja in medicinske tehnologije za ohranjanje človekovega zdravja.
High-throughput research: to catalyse progress in fundamental genomics (genome and post-genome) and biomedical research by enhancing data generation, standardisation, acquisition and analysis.
Zahtevne proizvodne raziskave: pospeševanje napredka v temeljni genomiki (genomiki in postgenomiki) in biomedicinskih raziskavah s pomočjo izboljšanja postopka priprave, standardizacije, pridobivanja in analiziranja podatkov.
Detection, diagnosis and monitoring: with emphasis on non-invasive or minimally invasive approaches and technologies such as new preventive tools for regenerative medicine (e.g. through molecular imaging and diagnostics).
Odkrivanje, diagnoza in spremljanje: s poudarkom na neinvazivnih ali invazivnih pristopih v majhnem obsegu ter tehnologijah, kot so nova preventivna orodja za regenerativno medicino (npr. z molekularnim prikazovanjem in diagnostiko).
Predicting suitability, safety and efficacy of therapies: to develop and validate biological markers, in vivo and in vitro methods and models, including simulation, pharmacogenomics, targeting and delivery approaches and alternatives to animal testing.
Predvidevanje primernosti, varnosti in učinkovitosti terapij: razvijanje in potrjevanje bioloških označevalcev, metod in modelov in vivo ter in vitro, vključno s simulacijo, farmakogenomiko, ciljno usmerjenimi pristopi in pristopi oskrbe ter alternativami za poskuse na živalih.
Innovative therapeutic approaches and intervention: to research, consolidate and ensure further developments in advanced therapies and technologies with potential application in many diseases and disorders such as new therapeutic tools for regenerative medicine.
Inovativni terapevtski pristopi in posegi: raziskave, krepitev in zagotavljanje nadaljnjega razvoja naprednih terapij in tehnologij z možnostjo uporabe pri številnih boleznih in zdravstvenih motnjah, kot so na primer nova terapevtska orodja za regenerativno medicino.